Correlation of AS160 hyperphosphorylation and 18FFDG uptaking in invasive breast cancer

doi:10.3760/cma.j.issn.1673422X.2017.03.004

Abstract

Abstract: ObjectiveTo investigate the correlation between AS160 hyperphosphorylation and 18Ffluorodeoxyglucose (18FFDG) uptaking in invasive breast cancer. MethodsThirtynine primary breast caner patients received PET/CT scan before operation and their maximum standard uptake values (SUVmax) were recorded. The levels of pAS160 (Thr642) were detected using immunohistochemical method in breast cancer tissues. The association between pAS160 (Thr642) levels and SUVmax was assessed using the Spearman nonparametric test. ResultsThe 18FFDG uptake of tumors of the 39 patients with primary breast caner was 6.1±2.7 (SUVmax). There was one false negative case in PET/CT scan imaging, compared with postoperative pathologic result. The positive rate of pAS160 (Thr642) was 76.9%, and it was positively correlated with SUVmax (r=0.672, P<0.001). ConclusionAS160 plays a significant role in the glucose metablism of breast cancer tissues and its hyperphosphorylation may contribute to the increased uptaking of glucose in patients with breast cancer.

Key words: Breast neoplasms, Phosphorylation, Fluomdeoxyglucose F18, AS160

Wei Yu, Jiang Xiaohua, Ma Ning, Cheng Yi, Lyu Guifang, Wang Wei, Zhao Jinfen. Correlation of AS160 hyperphosphorylation and 18FFDG uptaking in invasive breast cancer[J]. Journal of International Oncology, 2017, 44(3): 173-176.

References

［1］ Rockall AG, Avril N, Lam R, et al. Repeatability of quantitative FDGPET/CT and contrastenhanced CT in recurrent ovarian carcinoma: testretest measurements for tumor FDG uptake, diameter, and volume［J］. Clin Cancer Res, 2014, 20(10): 2751-2760. DOI: 10.1158/10780432.CCR132634. ［2］ Geraghty KM, Chen S, Harthill JE, et al. Regulation of multisite phosphorylation and 1433 binding of AS160 in response to IGF1, EGF, PMA and AICAR［J］. Biochem J, 2007, 407(2): 231-241. DOI: 10.1042/BJ20070649. ［3］ Jiang XH, Sun JW, Xu M, et al. Frequent hyperphosphorylation of AS160 in breast cancer［J］. Cancer Biol Ther, 2010, 10(4): 362-367. ［4］ Upadhyay M, Samal J, Kandpal M, et al. The warburg effect: insights from the past decade［J］. Pharmacol Ther, 2013, 137(3): 318-330. DOI: 10.1016/j.pharmthera.2012.11.003. ［5］ Nakano I. Therapeutic potential of targeting glucose metabolism in glioma stem cells［J］. Expert Opin Ther Targets, 2014, 18(11): 1233-1236. DOI: 10.1517/14728222.2014.944899. ［6］ Reiss K, Del Valle L, Lassak A, et al. Nuclear IRS1 and cancer［J］. J Cell Physiol, 2012, 227(8): 2992-3000. DOI: 10.1002/jcp.24019. ［7］ Aleskandarany MA, Rakha EA, Ahmed MA, et al. Clinicopathologic and molecular significance of phosphoAkt expression in early invasive breast cancer［J］. Breast Cancer Res Treat, 2011, 127(2): 407-416. DOI: 10.1007/s105490101012y. ［8］ Yang S, Ji M, Zhang L, et al. Phosphorylation of KIBRA by the extracellular signalregulated kinase (ERK)ribosomal S6 kinase (RSK) cascade modulates cell proliferation and migration［J］. Cell Signal, 2014, 26(2): 343-351. DOI: 10.1016/j.cellsig.2013.11.012. ［9］ Sommer EM, Dry H, Cross D, et al. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors［J］. Biochem J, 2013, 452(3): 499-508. DOI: 10.1042/BJ20130342. ［10］ Szablewski L. Expression of glucose transporters in cancers［J］. Biochim Biophys Acta, 2013, 1835(2): 164-169. DOI: 10.1016/j.bbcan.2012.12.004. ［11］ Shibata K, Kajiyama H, Mizokami Y, et al. Placental leucine aminopeptidase (PLAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia［J］. Gynecol Oncol, 2005, 98(1): 11-18. DOI: 10.1016/j.ygyno.2005.03.043. ［12］ Cheng JC, Mcbrayer SK, Coarfa C, et al. Expression and phosphorylation of the AS160_v2 splice variant supports GLUT4 activation and the Warburg effect in multiple myeloma［J］. Cancer Metab, 2013, 1(1): 14. DOI: 10.1186/20493002114. ［13］ Soussan M, Orlhac F, Boubaya M, et al. Relationship between tumor heterogeneity measured on FDGPET/CT and pathological prognostic factors in invasive breast cancer［J］. PLoS One, 2014, 9(4): e94017. DOI: 10.1371/journal.pone.0094017. ［14］ Gongpan P, Lu Y, Wang F, et al. AS160 controls eukaryotic cell cycle and proliferation by regulating the CDK inhibitor p21［J］. Cell Cycle, 2016, 15(13): 1733-1741. DOI: 10.1080/15384101.2016.1183853. ［15］ Mcbrayer SK, Cheng JC, Singhal S, et al. Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporterdirected therapy［J］. Blood, 2012, 119(20): 4686-4697. DOI: 10.1182/blood201109377846. ［16］ Zhang D, Li J, Wang F, et al. 2DeoxyDglucose targeting of glucose metabolism in cancer cells as a potential therapy［J］. Cancer Lett, 2014, 355(2): 176-183. DOI: 10.1016/j.canlet.2014.09.003.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Zhang Jinnan, Liu Bangqing, Li Jun, Liu Xiaohui. Research on BHLHE40 targets HMGA2 to reduce the sensitivity of thyroid cancer cells to cisplatin through activating the oxidative phosphorylation pathway [J]. Journal of International Oncology, 2023, 50(7): 398-406.
[11]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[12]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[13]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[14]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[15]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.